Petros Pharmaceuticals, Inc.

( )
PTPI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -2.01%167.240.7%$966.93m
ABBVAbbVie, Inc. 0.81%142.081.9%$836.18m
PFEPfizer Inc. -3.26%48.320.9%$816.98m
LLYEli Lilly & Co. -1.03%301.461.1%$775.81m
MRKMerck & Co., Inc. -0.30%88.920.7%$771.89m
BMYBristol-Myers Squibb Co. -0.52%74.471.0%$667.79m
SIGASIGA Technologies, Inc. 8.25%24.790.0%$465.44m
AZNAstraZeneca Plc -1.80%64.651.0%$355.61m
ALNYAlnylam Pharmaceuticals, Inc. -1.13%229.398.2%$281.63m
GBTGlobal Blood Therapeutics, Inc. -0.40%66.575.6%$275.23m
GSKGSK Plc -6.67%35.750.3%$212.12m
HZNPHorizon Therapeutics Plc -1.92%67.105.4%$208.58m
NVONovo Nordisk A/S 1.20%108.800.1%$177.13m
NVSNovartis AG -2.23%85.480.2%$175.53m
CCXIChemoCentryx, Inc. -0.53%50.602.9%$174.75m

Company Profile

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.